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ABSTRACT                        A lot of information is spread all over the world by papers and by other media 
about oxidative stress and antioxidant defence as well as their connection to human health and 
diseases, although only a few examine redox homeostasis from this point of view, because of 
expenses. We offer a cost efficient simple methodological triad “DPPH radical scavenging abil-
ity, reducing power and induced chemiluminescent intensity” in plasma and red blood cells as a 
program to evaluate the individual requirements for correct self control. We are able to evaluate 
with these global methods the differences between redox homeostasis of inactive, moderate and 
severe phase of IBD patients, a circadian rhythm in seasons of patients, deviant food consumes 
and initial state of tumourous processes as well as post operative and metastatic states.
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Materials and Methods 
Figure 1. Glutathione peroxidase activity of red blood cells.
Figure 2.  Superoxide dismutase activity of red blood cells.
Figure 3. Tumour markers in other patients without tumours.
             
variable
Correlations of redox parameters of treated tumourous 
patients. Marked correlations are significant at p<0.05




RBCCL  1.00  0.14 -0.22 -0.26 -0.06  0.14
TAS  0.14  1.00  0.15 -0.13  0.09 -0.19
Bile acid -0.22  0.15  1.00 -0.27 -0.24 -0.47
SOD -0.26 -0,13 -0.27  1.00  0.47  0.38
GSHPx -0.06  0.09 -0.24  0.47  1.00  0.29
PlasmaCL  0.14 -0.19 -0.47  0.38  0.19  1.00
Table 1. Significant correlations in tumourous patients.
RBCCL  = red blood cell chemiluminescence; TAS = total antioxidant status; Plas-
maCL = plasma chemiluminescence.
Results and Discussion
Figure 4. Tumour markers in colon tumourous patients examined by 
chance.
Figure 5. Tumour markers in treated colon tumourous patients.
Figure 6. Tumour markers in colon metastases.
Figure 7. Stimulated chemiluminescence in red blood cells of patients 
with different gastrointestinal diseases.
CRP = C-reactive protein; RBCCL = red blood cell chemiluminescence; HGB = haemoglobin; HTC = haematocrit; K = potassium; Na = sodium; PFSHG = plasma free SH 
group; PHDA = plazma H-donating ability; PRP = plasma reducing power; RBC = red blood cell; TP = total protein; UA = uric acid.
positive correlation negative correlation
UA–HGB (r = 0.7913;  p = 0.004) RBCCL–UA (r = -0.7743;  p = 0.009)
UA–HCT (r = 0.8332;  p = 0.001) RBCCL – HGB (r = -0.8214;  p = 0.004)
UA–PHDA (r = 0.6328;  p = 0.020) RBCCL – CRP (r = -0.8987;  p < 10– 4)
UA–PRP (r = 0.6229;  p < 10– 4) RBCCL – PHDA (r = -0.8281;  p = 0.003)
PFSHG–Na (r = 0.7472;  p = 0.013) RBCCL –PRP (r = -0.8942;  p < 10–4)
PHDA– PRP (r = 0.8780;  p < 10– 4) RBCCL –HTC (r = -0.8131;  p = 0.004)
RBC–HCT (r = 0.6103;  p = 0.046) PHDA – TP (r = -0.5783;  p = 0.038)
PHDA -K (r = 0.7040;  p = 0.016)
Table 2. Significant correlations in IBD.
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